Specialized Pro-Resolving Mediators
Specialized Pro-Resolving Mediators(特异性促炎症消退介质)
Specialized Pro-Resolving Mediators 相关产品(49)
- GC18552Lipoxin A4CAS: 89663-86-5纯度: >95.00%
Produced by the metabolism of 15-HETE or 15-HpETE with leukocytes
- GC26233Docosahexaenoic Acid-d5CAS: 1197205-71-2纯度: >99.00%
Docosahexaenoic acid-d5 (DHA-d5) is intended for use as an internal standard for the quantification of DHA (Item No. 90310) by GC- or LC-MS.
- GC4097110(S),17(S)-DiHDHACAS: 871826-47-0纯度: >98.00%
A DHA derivative with anti-inflammatory and anti-platelet activity
- GC40982Resolvin D5CAS: 578008-43-2纯度: >95.00%
A potent anti-inflammatory, pro-resolving lipid mediator
- GC4122717(R)-Resolvin D1 methyl esterCAS: 937738-64-2纯度: >95.00%
Methyl ester of an aspirin-triggered resolvin
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC18552 | Lipoxin A4 | 89663-86-5 | >95.00% | |
Produced by the metabolism of 15-HETE or 15-HpETE with leukocytes | ||||
| GC18680 | Lipoxin A4 methyl ester | 97643-35-1 | >95.00% | |
A lipid soluble, prodrug of LXA 4 | ||||
| GC18681 | Lipoxin B4 | 98049-69-5 | >95.00% | |
A positional isomer of LXA 4 | ||||
| GC26233 | Docosahexaenoic Acid-d5 | 1197205-71-2 | >99.00% | |
Docosahexaenoic acid-d5 (DHA-d5) is intended for use as an internal standard for the quantification of DHA (Item No. 90310) by GC- or LC-MS. | ||||
| GC40609 | Lipoxin A5 | 110657-98-2 | >95.00% | |
An EPA-derived bronchoconstrictor | ||||
| GC40971 | 10(S),17(S)-DiHDHA | 871826-47-0 | >98.00% | |
A DHA derivative with anti-inflammatory and anti-platelet activity | ||||
| GC40975 | 17(S)-HpDHA | 123673-33-6 | >98.00% | |
A mono-oxygenation product of DHA | ||||
| GC40978 | 7-epi Maresin 1 | 1268720-66-6 | >95.00% | |
An inactive Maresin 1 epimer | ||||
| GC40980 | Maresin 2 | 1639809-46-3 | ≥95.00% | |
A 13R,14S-dihydroxy DHA produced by macrophages | ||||
| GC40981 | Protectin D1 | 660430-03-5 | >98.00% | |
A specialized pro-resolving mediator | ||||
| GC40982 | Resolvin D5 | 578008-43-2 | >95.00% | |
A potent anti-inflammatory, pro-resolving lipid mediator | ||||
| GC41169 | Lipoxin B4 methyl ester | 97589-07-6 | >95.00% | |
A lipid soluble prodrug of LXB 4 | ||||
| GC41206 | 14(S)-HDHA | 119433-37-3 | >98.00% | |
An anti-inflammatory lipid produced by macrophages | ||||
| GC41207 | 17(R)-HDHA | 155976-53-7 | >98.00% | |
An aspirin-induced DHA metabolite | ||||
| GC41208 | 17(S)-HDHA | 92693-03-3 | >98.00% | |
An oxidation product of DHA | ||||
| GC41227 | 17(R)-Resolvin D1 methyl ester | 937738-64-2 | >95.00% | |
Methyl ester of an aspirin-triggered resolvin | ||||
| GC41230 | Resolvin D1 methyl ester | 937738-63-1 | >97.00% | |
Derivative of resolvin D1 | ||||
| GC41231 | Resolvin D2 methyl ester | 810668-53-2 | >95.00% | |
Methyl ester form of RvD2 | ||||
| GC41232 | Resolvin D3 methyl ester | - | >95.00% | |
A methyl ester form of resolvin D3 | ||||
| GC41415 | 15(R)-Lipoxin A4 | 171030-11-8 | >95.00% | |
An aspirin-triggered lipoxin | ||||
| GC41424 | 6(S)-Lipoxin A4 | 94292-80-5 | >95.00% | |
An isomer of LXA 4 | ||||
| GC41951 | 17(R)-Resolvin D1 | 528583-91-7 | >95.00% | |
An aspirin-triggered epimer of RvD1 | ||||
| GC41952 | 17(R)-Resolvin D4 | 528583-89-3 | >98.00% | |
An aspirin-triggered epimer of RvD4 | ||||
| GC44138 | MCTR1 | 1784701-61-6 | ≥95% | |
A specialized pro-resolving mediator | ||||